Journal
JOURNAL OF HEART AND LUNG TRANSPLANTATION
Volume 41, Issue 10, Pages 1401-1413Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.healun.2022.06.019
Keywords
microRNA; heart transplantation; allograft rejection; biomarker
Ask authors/readers for more resources
By analyzing and studying miR expression data in heart transplant patients, miR panels with high diagnostic accuracy for acute rejection can be developed, providing a new non-invasive method for clinical monitoring of heart transplant.
BACKGROUND: Noninvasive monitoring of heart allograft health is important to improve clinical out-comes. MicroRNAs (miRs) are promising biomarkers of cardiovascular disease and limited studies suggest they can be used to noninvasively diagnose acute heart transplant rejection. METHODS: The Genomic Research Alliance for Transplantation (GRAfT) is a multicenter prospective cohort study that phenotyped heart transplant patients from 5 mid-Atlantic centers. Patients who had no history of rejection after transplant were compared to patients with acute cellular rejection (ACR) or antibody-mediated rejection (AMR). Small RNA sequencing was performed on plasma samples col-lected at the time of an endomyocardial biopsy. Differential miR expression was performed with adjustment for clinical covariates. Regression was used to develop miR panels with high diagnostic accuracy for ACR and AMR. These panels were then validated in independent samples from GRAfT and Stanford University. Receiver operating characteristic curves were generated and area under the curve (AUC) statistics calculated. Distinct ACR and AMR clinical scores were developed to translate miR expression data for clinical use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available